Galera Therapeutics, Inc.

Galera Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing therapies for difficult-to-treat breast cancers. After acquiring Nova Pharmaceuticals in late 2024, the company shifted its strategy toward a pan-NOS inhibitor program and retained two SOD mimetic assets from its earlier portfolio.

11.00

— Galera Therapeutics, Inc.
	%
Pan-NOS inhibitor program	45% Clinical-stage nitric oxide synthase inhibitor being developed for advanced breast cancer indications.
SOD mimetic oncology assets	35% Legacy small-molecule dismutase mimetics, including avasopasem, supported mainly through clinical supply commitments.
Clinical development services	20% Company-run and investigator-sponsored trial support, including drug supply, protocol support and development oversight.

Galera does not sell commercial products today; its primary counterparties are clinical investigators, research...

Investigator-sponsored trial sitesprimary
Academic hospitals and investigators receive drug supply and study support for NIH-funded breast cancer trials.
Clinical research consortiaprimary
Collaborative networks such as I-SPY 2 help test the pan-NOS inhibitor in broader TNBC populations.
Oncology treatment centerssecondary
Cancer centers are the eventual end users if the company secures regulatory approval and commercialization.
Contract research and manufacturing partnersprimary
CROs, CMOs and consultants are paid to run studies, manufacture materials and support development.

Galera is headquartered in the United States and its development activity is centered on U.S...

•Headquartered in the United States
•Clinical trial activity centered in Houston, Texas
•U.S.-based NIH-funded investigator studies
•OTCQB listing in the U.S. capital markets
•No disclosed commercial geography because the company is pre-revenue

The company’s strategy changed materially after the Nova acquisition, with a new focus on advanced breast cancer...

Advance the pan-NOS inhibitor in MpBCshort-term

This is the lead asset and the main source of future value creation.

Expand development into TNBCmedium-term

Broader TNBC activity could enlarge the addressable patient population and improve partnering appeal.

Maintain capital efficiencyshort-term

The company has limited cash and needs to extend runway while advancing clinical milestones.

Galera remains a high-risk clinical-stage biotech with no commercial revenue and a heavy dependence on successful trial...

critical

Clinical development failure

The company’s value depends on positive results from early-stage oncology trials.

Scope: Lead pan-NOS inhibitor and legacy SOD mimetics
Materiality: high

high

Going-concern and financing risk

Cash resources are limited and the company may need additional capital before commercialization.

Scope: Operating runway and future trial funding
Materiality: high

high

Regulatory and trial execution risk

Enrollment, protocol changes, safety findings and regulatory requirements can delay or derail studies.

Scope: MpBC, TNBC and HR+ breast cancer programs
Materiality: high

medium

Dependence on external collaborators

Key studies rely on NIH grants, investigators and consortium partners rather than fully internal execution.

Scope: Houston Methodist, I-SPY 2 and other trial sites
Materiality: medium

Research and development expense recognition

Quarterly volatility in operating expense and net loss

Going-concern assessment

Important for liquidity disclosure and financing risk

Share-based compensation

Affects both R&D and G&A expense

Acquisition and asset valuation

Could affect intangible asset carrying values and future impairment risk

Galera Therapeutics, Inc.

Clinical development failure

Going-concern and financing risk

Regulatory and trial execution risk

Dependence on external collaborators

Aldeyra Therapeutics, Inc.

GALECTIN THERAPEUTICS INC

AMICUS THERAPEUTICS, INC.

CalciMedica, Inc.

Entrada Therapeutics, Inc.

Protara Therapeutics, Inc.